SENSEX NIFTY
Sep 08, 2011, 03.47 PM IST | Source: Moneycontrol.com

Nectar Lifesciences manufacturing unit gets US FDA nod

Nectar Lifesciences has received US Food and Drugs Administration (FDA) approval for its Active Pharmaceutical Ingredients (API) manufacturing plant Unit-II in Dera Bassi, Punjab.

Nectar Lifesciences manufacturing unit gets US FDA nod
Moneycontrol Bureau

Nectar Lifesciences has received US Food and Drugs Administration (FDA) approval for its Active Pharmaceutical Ingredients (API) manufacturing plant Unit-II in Dera Bassi, Punjab.

Nectar Lifesciences hit the 20% upper circuit at Rs 23 on NSE post the announcement in afternoon trade.

This facility has also been approved by Japan’s ministry of health, Medical Control Council of South Africa and Korean FDA, Nectar Lifesciences said Thursday.

The company’s API as well as formulations facilities have been successfully inspected by European Union authorities and it is awaiting final approval from them, it said.

Nectar Lifesciences said these approvals will help it tap the more profitable regulated markets and thus sustain the growth delivered by its API business.

The company aims to file 20 drug master files (DMF) and 10 abbreviated new drug applications (ANDA) from its Dera Bassi and Baddi facilities in the current fiscal. So far it has filed 21 DMFs and 6 ANDAs in highly regulated markets, Nectar Lifesciences said.

Nachiket Kelkar
nachiket.kelkar@network18online.com

Nectar Life stock price

On July 30, 2014, at 13:04 hrs Nectar Lifesciences was quoting at Rs 26.60, down Rs 0.65, or 2.39 percent. The 52-week high of the share was Rs 35.00 and the 52-week low was Rs 9.65.


The company's trailing 12-month (TTM) EPS was at Rs 2.77 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 9.6. The latest book value of the company is Rs 41.46 per share. At current value, the price-to-book value of the company is 0.64.

Set email alert for

ADS BY GOOGLE

video of the day

See 20-30% growth for Indian mkt over few years: Mobius

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.